Wallace K. Reams, Former President of Aveva Drug Delivery Systems, Joins Transdermal Delivery Solutions Board of Advisors
Business Wire: August 25, 2016 – PALM BEACH GARDENS, FL, U.S.A. – Transdermal Delivery Solutions Corporation (TDSC), www.TDSC.us, announced today that transdermal delivery veteran Wallace K. “Wally” Reams has joined its Board of Advisors.
Reams (www.linkedin.com/in/wreams) led the acquisition of Aveva Drug Delivery Systems Inc., a Florida-based developer and manufacturer of transdermal patches, for Nitto Denko Corporation, where as president and COO from 2003 to 2014 he successfully launched products for pain management, hypertension, antiemesis (resulting from chemotherapy), and smoking cessation.
“We are very pleased to have Wally Reams, a veteran transdermal delivery industry professional, join our Board of Advisors. His years of experience as COO of Aveva, as well as his reputation, relationships, and track-record of success in the pharmaceutical and medical device industries, will be an invaluable asset to our organization moving forward,” said Kenneth Kirby, president of TDSC.
Mr. Reams has 30+ years of experience in the pharmaceutical (transdermal drug delivery), medical device (wound care), and industrial products areas. He has demonstrated success in start-up and turnaround, new business development, strategic alliance, and development of high-quality senior management teams. He has extensive international experience, managing a strategic alliance in Japan, global distribution, and in his role of Directeur Général (president) of Brady SARL successfully led a turnaround and restructuring of a manufacturing and marketing company in Jouy-le-Potier, France.
“I am excited to join Ken and the TDSC team and look forward to helping move this paradigm-shifting platform technology to the market,” said Mr. Reams. “From my perspective of many years in development of patch-based transdermal delivery products, I can honestly say the HypoSpray® technology leaps past the state of the art and will enable delivery of compounds and classes of drugs not possible with patches. This has the potential to revolutionize medicine, and I am very pleased to be a part of it.”
TDSC is committed to advancing the science of transdermal drug delivery using its patented spray-on delivery system platform, HypoSpray® . TDSC’s proprietary system enables a much larger number of medications to be delivered directly through the skin, for systemic or localized application, utilizing its rapid acting, patchless, spray-on technology. TDSC’s technology represents a paradigm shift in drug delivery. www.tdsc.us/lower.php?url=tdsc-platform
